Introduction
Vascular smooth muscle cells (SMCs [VSMCs] ) can switch between differentiated (contractile) and dedifferentiated (syn thetic migratory) phenotypes (Gimona et al., 1990; Sobue et al., 1999) . Migration of SMCs plays a critical role in many physio logical and pathological processes, including atherosclerosis, angiogenesis, smooth muscle hypertrophy, and hyperplasia. PDGF is one of the most potent stimuli for migration of mesen chymal cell types, including VSMCs. Furthermore, excessive PDGF production has been implicated in several pathological vascular disorders (Alvarez et al., 2006; Andrae et al., 2008) .
An important morphological feature of VSMCs migrating in vitro is a membrane structure called a podosome (Gimona et al., 2003; Linder and Aepfelbacher, 2003) . Podosomes are dynamic, shortlived, actinrich protrusions of the plasma mem brane, which are thought to mediate adhesion to and, in some cases, degradation of the surrounding extracellular matrix. Podosomes are also found in other migratory cells such as monocytes and endothelial cells (Gimona et al., 2008) . Many types of human cancer cells as well as Rous sarcoma virustransformed fibroblasts form highly related structures, termed invadopodia, whose presence is correlated with invasive and metastatic behavior (Gimona et al., 2008) .
MicroRNAs (miRs) are 20-25ntlong noncoding RNAs that negatively regulate gene expression by binding to sites in the 3 untranslated region (UTR) of target mRNAs (Bartel, 2004) . These small RNA molecules are involved in processes such as cell differentiation and proliferation (Chen et al., 2004) . Recently, we and others (Boettger et al., 2009; Cheng et al., 2009; Cordes et al., 2009; Elia et al., 2009b; Xin et al., 2009) have shown that miR143 and 145 regulate the VSMC phenotypic switch from a contractile/nonproliferative to a migrating/proliferative state (Owens, 1995) . miR143 and 145 are organized in a cluster transcribed from the same primary miR S mooth muscle cell (SMC) plasticity plays an important role during development and in vascular pathologies such as atherosclerosis and restenosis. It was recently shown that down-regulation of microRNA (miR)-143 and -145, which are coexpressed from a single promoter, regulates the switch from contractile to synthetic phenotype, allowing SMCs to migrate and proliferate. We show in this study that loss of miR-143/145 in vitro and in vivo results in the formation of podosomes, which are actin-rich membrane protrusions involved in the migration of several cell types, including SMCs. We further show that platelet-derived growth factor (PDGF) mediates podosome formation in SMCs through the regulation of miR-143/145 expression via a pathway involving Src and p53. Moreover, we identify key podosome regulators as targets of miR-143 (PDGF receptor  and protein kinase C ) and miR-145 (fascin). Thus, dysregulation of the miR-143 and -145 genes is causally involved in the aberrant SMC plasticity encountered during vascular disease, in part through the up-regulation of an autoregulatory loop that promotes podosome formation.
MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro whereas overexpression of Ad-miR208 had no effect (Fig. S2 A) . Thus, Srcmediated downregulation of the miR-143/145 gene is required for the formation of podosomes. Together, these observations strongly suggest a key role for these miRs in regu lating podosome formation in VSMCs.
Previously, we demonstrated the role of the miR143/145 cluster in maintaining the differentiation status of VSMCs and proposed that their dysregulation underlies the histological changes observed in vessels in pathologies such as atherosclero sis and restenosis (Elia et al., 2009b) . In this study, we show the ability of these cells to form podosomes, which are structures involved in cell migration and invasiveness, in vitro and in vivo. This is the first direct correlation between podosome formation and vascular pathologies such as atherosclerosis and restenosis. The miR143/145 cluster has also been documented to play an important role in cancer. Dysregulation of miR143 and 145 as the result of chromosomal deletion at 5q32 occurs in colon (Michael et al., 2003) and breast (Iorio et al., 2005) adenocarci nomas. Most B cell malignancies (Akao et al., 2007) and cancer cell lines (Michael et al., 2003) have downregulation of both miRs. The presence of invadopodia, which are structurally related to podosomes, has been correlated with invasiveness of cancer cells (Weaver, 2006) . In the future, it will be important to determine whether miR143 and 145, or indeed other miRs, regulate invadopodia formation and invasiveness in human cancer cells.
PDGF regulates miR-143 and -145
expression through Src and p53 activity PDGF is a known regulator of SMC differentiation and migra tion (Owens et al., 2004) , and Src is known to be a key media tor of the PDGF signal transduction pathway (Bromann et al., 2004) . Previous studies have shown that Src family kinase sig naling is required to elicit both mitogenicity and motogenicity in response to PDGF (Kypta et al., 1990; Twamley et al., 1992; Klinghoffer et al., 1999) . It has also been shown that PDGF can reduce miR145 expression (Cheng et al., 2009) . In this study, we found that PDGF had a similar effect on miR143 (Fig. 2 B) . Because we demonstrated that activated Src is able to downregulate miR143/145, we next tested whether Src activation is the mechanism by which PDGF regulates these genes. Treatment with the Src family kinase inhibitor SU6656 (Blake et al., 2000) restored miR143 and 145 levels in PDGF treated cells (Fig. 2 B) . In contrast, the PI3K (phosphatidyl inositol 3kinase) inhibitor LY294002 had no effect. Next, we asked how Src regulates these two miRs. It has been shown that, once activated by PDGF, Src activity overcomes a p53 mediated inhibition of cell cycle progression and that inhibition of p53 expression is a key phenomenon for Srcmediated podosome formation (Mukhopadhyay et al., 2009 ). Moreover, p53 activity increases miR143 and 145 levels in cancer cells in a manner that does not involve transcription (Suzuki et al., 2009) . We hypothesized that in response to PDGF, Src downregulates miR expression through p53 inhibition. In keeping with this, doxorubicin, a known p53 activator, restored miR143 and 145 levels in PDGF stimulated cells (Fig. S2 B) . (Cordes et al., 2009; Xin et al., 2009) . In this study, we have used the knockout (KO) mouse we generated, referred to as the miR143(145) KO, in which the expression of both miRs is prevented, to investigate the molecular mechanism under lying the regulation of migration by miR143/145.
Results and discussion
The miR-143/145 gene products inhibit podosome formation in VSMCs
VSMCs form podosomes when they migrate and invade, so we first tested whether expression of these miRs affects podo some formation. Primary mouse aorta SMCs cultured on glass coverslips contained prominent actin stress fibers and large vinculincontaining focal adhesions. However, some (7.6 ± 2.5%) of the primary VSMCs obtained from miR143(145) KO mouse aortas also contained podosomelike structures at the cell periphery ( Fig. 1 A) . Treatment with phorbol dibutyrate (PDBu), a known inducer of podosomes in SMCs (Gimona et al., 2003) , greatly increased the number of KO cells presenting with these structures (91.3 ± 3.2%). These podosomes were organized into rings (known as rosettes), clusters of rosettes, and occa sionally peripheral actin belts reminiscent of the structures de scribed in primary osteoclasts (Fig. S1 A; Destaing et al., 2003) . This was in stark contrast to PDButreated wildtype (WT) VSMCs, in which podosomes were present in <10% of the cells and found in a scattered dotlike conformation. Colocal ization of proteins known to be expressed in podosomes such as cortactin, vinculin, and Tks5 (Linder and Aepfelbacher, 2003; Seals et al., 2005) confirmed that these structures were in fact podosomes (Fig. 1 B) . To determine whether miR143/145 loss facilitated podosome formation, we restored miR143 or 145 expression in the miR143(145) KO VSMCs with the recombinant adenoviruses Ad-miR143 or -miR145. Transduction with either virus completely abrogated podo some formation (Fig. S1 B) , whereas a control miR208 had no effect.
Next we analyzed aortas from miR143(145) KO and WT mice by immunoelectron microscopy to determine whether podosomes formed in vivo. KO SMCs showed the formation of circular structures remarkably similar to the ones observed in vitro. These structures costained for the podosome proteins cortactin and Tks5 and were not observed in the aortas of WT littermates ( Fig. 1 C) . These data suggest that podosomes form in vivo, that their morphological characteristics are retained in tissue culture, and that miR143/145 controls podosome forma tion in vivo and in vitro.
Src tyrosine kinase activity promotes podosome forma tion (Gimona et al., 2008) ; the established VSMC line A7r5 forms abundant rosettes of podosomes when transformed with the constitutively active Src mutant, SrcY527F (Furmaniak Kazmierczak et al., 2007) . We found that Srctransformed A7r5 cells had reduced expression of miR143 and 145 com pared with the parental cell line and that miR expression was partially restored by treatment with the Src inhibitor PP2 (Fig. 2 A) . In addition, overexpression of either Ad-miR143 or -miR145 inhibited the formation of podosome rosettes, product derived from p53RE2 using two different antibodies against p53 (Fig. 2 F) . Collectively, these data suggest that p53 can transcriptionally regulate miR143/145 expression through p53RE2.
Excessive activity of PDGF has been associated with several human disorders, including atherosclerosis and resteno sis (Alvarez et al., 2006; Andrae et al., 2008) , at least in part through the regulation of SMC plasticity. The mechanism un derling this phenomenon is not completely understood, but it was recently shown that miR143 and 145 regulate the SMC switch from contractile to synthetic phenotype (Boettger et al., 2009; Cheng et al., 2009; Cordes et al., 2009; Elia et al., 2009b; Xin et al., 2009) . In this study, we show for the first time that PDGF is able to regulate miR143/145 expression via a pathway
We analyzed the promoter region of the primary miR gene encoding miR143/145 and identified two potential binding sites for p53 (Fig. 2 C) . To define the role of these potential p53 response elements (p53REs) in miR143/145 induction, we cloned a fragment from rat chromosome 18 containing the two potential p53binding sites into a luciferase vector and evalu ated promoter activity by luciferase assay. As shown in Fig. 2 D, p53 activation by doxorubicin treatment induced a marked ele vation of miR143/145 promoter activity. Deletion of p53RE2 resulted in total inhibition of promoter activity, whereas dele tion of p53RE1 had no effect (Fig. 2 E) . To test whether p53 can bind the p53RE2 sequence in the endogenous promoter sequence of miR-143/145, we performed chromatin immuno precipitation (ChIP) assays. We detected one specific PCR in mRNA levels (Fig. 4 A and Fig. S3 B) . Luciferase assays with WT and mutated 3 UTR-binding sites confirmed that these mRNAs are targets for miR143 and 145 (Fig. 4 B) . All three proteins were upregulated in KO VSMCs (Fig. S3 C) . Both PKC and fascin were localized to podosomes of miR143 (145) KO VSMCs (Fig. S3 D) , and RNA interference of either gene reduced podosome formation and migration in miR143 (145) KO VSMCs and Src3T3 cells (Fig. 4, C and D; and Fig. S3, E and F) .
The serine/threonine kinase PKC is involved in cell migration and proliferation. It is upregulated in skin cancer, where it is responsible for increased proliferation (Breitkreutz et al., 2007) . Although PKC activity is known to be required for podosome formation (Hai et al., 2002) , there are no prior studies on the involvement of this isoform. PDGFR is a receptor tyrosine kinase that stimulates both migration and pro liferation in response to ligand binding (Heldin and Westermark, 1999) . In SMCs, the likely ligand is PDGFAA (Barrett and Benditt, 1988) . Fascin is an actinbundling protein with roles in diverse forms of cell protrusions and in cytoplasmic actin bundles (Adams, 2004) . It has been shown to localize to the leading edge of cancer cells and play a role in their migration (Vignjevic et al., 2007) , but it has not previously been described to be involved in podosome formation. We show in this study that each of these targets is required for podosome formation in VSMCs, and their inhibition, at least in part, explains the role of the miR-143/145 gene as an inhibitor of cell migration.
We have demonstrated that Src activity can inhibit miR-143/145 gene expression, likely through the inhibition of p53 (Mukhopadhyay et al., 2009) , which is a direct transcrip tion factor for this gene cluster. Src is an activator of podosome formation in VSMCs (Gimona et al., 2008; Mukhopadhyay et al., 2009) , and it has been shown that the PKC induction of podosomes is a result of Src activation (Gatesman et al., 2004) and that Src and PKC can associate with each other (Vondriska et al., 2001) . Furthermore, Src family kinases are activated by PDGFRs (Kypta et al., 1990) , as is PKC (Ha and Exton, 1993) . We hypothesize the presence of an autoregula tory loop, initiated by PDGF production in response to ves sel injury. Stimulation of the PDGFR activates PKC and Src, which in turn promotes migration and podosome formation, in part through Src inhibition of p53 and thus miR143 and 145 expression. This allows the subsequent upregulation and Src phosphorylation of key podosome proteins as well as increased expression of the PDGFR, which further boosts signaling (Fig. 5 ).
Materials and methods

Materials
The following antibodies were used: cortactin, Tks5, and fascin (Millipore); vinculin, smooth muscle -actin, and CD31 (Sigma-Aldrich); PKC-, involving Src and p53. The mechanism by which Src regulates p53 level and/or function is the subject of active investigation in our laboratory. Nevertheless, these results open up new po tential avenues to use Src and/or p53 inhibitors to treat vascular pathologies (Elia et al., 2009b) .
PDGF induces podosome formation in SMCs through miR-143 and -145 down-regulation
PDGF is a known inducer of migration in SMCs, yet stimu lation of podosome formation by PDGF has not previously been described. We pretreated A7r5 cells with PDGF for 24 h (allowing the complete downregulation of the two miRs) and then treated the cells again with PDGF for 3 h more. After fixation and Factin staining, we observed punctate structures in the cells (57.3 ± 2.5%; Fig. 3 A) . In cells that were not pre treated with PDGF, far fewer cells (9.0 ± 3.6%) formed the same structures. When plated on gelatincoated glass cover slips, these punctate structures, which costained for cortac tin and Tks5, were able to digest the substrate (Fig. 3 B and Fig. S1 C) . Confocal microscopy demonstrated that the actin puncta colocalized in the same plane with the degradation spots ( Fig. S2 C) , confirming that they were indeed podosomes. Overexpression of miR143 or 145 during the PDGF treatment inhibited podosomes, demonstrating that the downregulation of miR143 and 145 is a key step in PDGFstimulated podo some formation (Fig. 3 C) . When the PDGF pretreatment was conducted in the presence of the Src inhibitor SU6656 or the p53 inducer doxorubicin, podosomes were not observed (Fig. 3 D) . Finally, in keeping with the notion that the 24 h of pretreatment with PDGF is required to downregulate the miRs, 80% of SMCs from miR143(145) KO mouse aortas formed podosomes after only 3 h of PDGF treatment (75.3 ± 5%; Fig. 3 E) . Before this study, only nonphysiological treatments such as phorbol esters had been shown to elicit podosome formation in SMCs. We speculate that the lengthy pretreat ment with PDGF and subsequent downregulation of the miRs might represent a physiological control mechanism that provides a threshold to be overcome to elicit the synthetic/ motile response.
Identification of targets of miR-143 and -145
Using bioinformatics to search for miR143 and 145 targets, we identified likely candidates to be PKC and PDGF recep tor  (PDGFR) for miR143 and fascin for miR145. These genes have highly conserved seed sequences for miR143 or 145 in a variety of species (Fig. S3 A) . Transduction of miR143(145) KO VSMCs with Ad-miR143 decreased the abundance of PKC and PDGFR, whereas transduction with Ad-miR145 decreased fascin without effecting a change (D and E) Measurements were calculated as the percentage of control (WT promoter without doxorubicin), and error bars were calculated as propagated standard errors of the mean of triplicate measurements from each experiment on 3T3 cells. *, P < 0.05. (F) ChIP assay confirms that p53 specifically interacts with p53-RE-2. Sequences from the upstream region of the rat miR-1 gene without p53-binding sites serve as a negative control. No Ab, isotypic IgG; Sc-99, p53 antibody clone sc-99; Sc-100, p53 antibody clone sc-100.
PDGF-BB, 10 µM PP2, 5 µM SU6656, 1 µM doxorubicin, 5 µM LY294002, and 10 µM UO126.
Cell lines
A7r5 rat SMCs and 3T3 cells were maintained in DME (Invitrogen) supplemented with 1.5 g/l-glucose, 4 mM l-glutamine, 10% fetal bovine serum, and penicillin/streptomycin at 37°C in a 5% CO 2 atmosphere. Primary VSMCs PDGF-R, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Cell Signaling Technology); and p53 clones sc-99 and sc-100 and isotypic IgG clone sc-2025 (Santa Cruz Biotechnology, Inc.). Secondary antibodies conjugated to Alexa Fluor 488 and 568 and Alexa Fluor 594-conjugated phalloidin were obtained from Invitrogen. PDBu, PDGF-BB, PP2, SU6656, doxorubicin, LY294002, and UO126 were purchased from Sigma-Aldrich and used at the following concentrations: 10 µM PDBu, 10 and 20 ng/ml dissected and fixed in 2% paraformaldehyde, 0.1% glutaraldehyde, and 0.1 M sodium phosphate in PBS, pH 7.2, for 24 h. After fixation, aortas were treated with 1% osmium tetrachloride and dehydrated using graded ethanol. The samples were then infiltrated with and embedded in LX112 epoxy resin (Ted Pella, Inc.). Ultrathin sections (83 nm) were made using an Ultracut II (Leica) and placed on 150-mesh nickel grids. Sections were then steamed for 20 min in a citrate-based antigen retrieval solution. When cool, the sections were then blocked using serum-free protein block. Each section was then probed for the primary antibodies for 2 h, followed by gold secondary antibodies (5-and 10-nm gold particle from Ted Pella, Inc.) at 1:20 dilution in TBS, pH 7.6, for 1 h. Sections were viewed, and images were obtained using an electron microscope (EM10C; Carl Zeiss, Inc.).
were obtained from WT and KO mouse aortas, and purity was assessed by staining with antibodies against smooth muscle -actin and CD31 as previously described (Ray et al., 2001 ). 99% of the cells were positive for smooth muscle -actin.
Animals
Animals were housed in accordance with the guidelines of the American Association for Laboratory Animal Care. The miR-143(145) KO mice were previously described (Elia et al., 2009b) .
Electron microscopy
Electronic microscopy was performed at the Veterans Medical Research Foundation, San Diego, CA. Adult aortas from WT and KO mice were Bioinformatics Potential miR-143 and -145 targets were identified using the algorithms miRanda (http://www.microrna.org), TargetScan (http://www.targetscan .org), and PicTar (http://pictar.mdc-berlin.de/) as previously described (Carè et al., 2007; Elia et al., 2009a) .
Formaldehyde cross-linking and ChIP assay ChIP assays were performed as previously described (Fazi et al., 2005) . In brief, cross-linking of proteins to DNA was obtained by the direct addition of formaldehyde to cultured cells (2 × 10 6 ) to a final concentration of 1%. After incubation for 10 min at 37°C, the mixture was sonicated, and chromatin was immunoprecipitated overnight with 5 µl of p53 antibodies. miR-143/145 promoter analysis was performed using MatInspector (http://www.genomatix.de/products/MatInspector). Binding sites were amplified using the primers p53-RE-2-5 (5-TAAGCCCCTCTCATCTC-CCAACAG-3), p53-RE-2-3 (5-GGAACAATGGGATGGGGAGGTATG-3), foxo3a-RE-5 (5-GACTCTGTATTAATCTGCTTTAC-3), and foxo3a-RE-3 (5-GCAGTGCTCAAATGGTACCAG-3).
Reporter assays
The miR-143/145 promoter, which contains two potential binding sites for p53, was amplified from rat chromosome 18 using KOD Taq polymerase (EMD) and the primers p53-5 (5-TAAGCCCCTCTCATCTCCCA-3) and p53-3 (5-GACTCCCAACTGACCAGAGA-3). The promoter was cloned into the reporter plasmid pGL3-basic (Promega). For the promoter experiment, 3T3 cells were seeded in 24-well plates (Nunc) and transfected with 100 ng of the miR-143/145 promoter-luciferase reporter construct and 10 ng of the renilla plasmid using Lipofectamine 2000 (Invitrogen) and then treated with 1 µM doxorubicin. The deleted promoter sequences were obtained using the primers BS1-5 (5-CCTCCCCATCCCATTGTTCC-3), BS1-3 (5-GACTCCCAACTGACCAGAGA-3), BS2-5 (5-TAAGC-CCCTCTCATCTCCCA-3), and BS2-3 (5-ACGTCCATCTTCGTGTCCT-TTG-3). For the 3 UTR reporter assay, experiments were performed in 3T3 cells. 3 UTR segments were subcloned by standard procedures into the psiCHECK-2 (Promega) immediately downstream of the stop codon of the renilla gene using the primers PKC--5 (5-GAGGCTGCTTCGGATG-GAGGGA-3), PKC--3 (5-TAAGATTTAACATCATCATATT-3), fascin-5 (5-GGCCACCTGCCCTCTGCAGG-3), fascin-3 (5-GGCCGCAGACT-TGATTTTAC-3), PDGF-R-5 (5-CTGACACGCTCCGGGTATCA-3), and PDGF-R-3 (5-AACGTTAAGTCATATATAAT-3). Seed sequence mutagenesis was performed as described by the manufacturer (Agilent Technologies). 3T3 cells were transfected with 10 ng of the reporter plasmid and 20 nM of the miR mimics or scrambled sequence (Thermo Fisher Scientific) using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Cells were lysed and assayed for luciferase activity at 48 h after transfection, and the luciferase gene coexpressed in the same plasmid was used as internal control. All luciferase assays were performed with Dual Luciferase kit (Promega) as previously described (Carè et al., 2007; Elia et al., 2009a) .
RNA interference
Smart pool siRNAs for scrambled, PKC-, and fascin were purchased from Thermo Fisher Scientific and transfected into Src-3T3 using Lipofectamine 2000. Lentiviruses with scrambled, PKC-, and fascin short hairpin RNA (shRNA) were purchased from Santa Cruz Biotechnology, Inc., and KO SMCs were infected at MOI 5 using 5 µg/ml polybrene. Cells were selected for puromycin resistance according to the manufacturer's protocol. RNA silencing was evaluated by qRT-PCR, and the residual levels of RNA for each target were as follows: PKC-, 15 ± 0.9 in Src-3T3 and 10 ± 1.3 in SMCs; and fascin, 34 ± 4 in Src-3T3 and 30 ± 1.4 in SMCs.
RNA quantification
For qRT-PCR analysis, total RNA was extracted using the TRIZOL reagent (Invitrogen) according to the manufacturer's protocol. cDNA was prepared using SuperScript Reverse transcription cDNA kit (Invitrogen). SYBR green qRT-PCR was performed using the primers PKC--5 (5-CTGGAC-GTGGACTCCTGATT-3), PKC--3 (5-ACTCAGGCTCCTTCCATCA-3), fascin-5 (5-AACCCCTTGCCTTTCAAACT-3), fascin-3 (5-CATGGAA-AGAAGGGGACAGA-3), PDGF-R-5 (5-AGGACTTGGGTGATGTG-GAG-3), PDGF-R-3 (5-TGTGGCCAGTCACTCTCTTG-3), GAPDH-5 (5-GACGGCCGCATCTTCTTGT-3), and GAPDH-3 (5-CACACCGACC-TTCACCATTTT-3). For miR qRT-PCR, total RNA was extracted using TRIZOL. Primers and probes specific for mouse/rat miR-143, -145, and -199 and internal control, Sno202 RNA, and U6 small nuclear RNA were purchased from Applied Biosystems. Amplification and detection was performed with a sequence detection system (model 7300; ABI) using 40 cycles of
Immunofluorescence (IF)
IF was performed on paraformaldehyde-fixed cells. Cells were permeabilized with 0.1% Triton X-100 in PBS and then blocked with 0.1% Triton X-100 and 5% BSA in PBS for 1 h, washed, and incubated overnight with the related antibody at 4°C. Antibodies conjugated to Alexa Fluor 488 and 568 were used as secondary antibodies. Actin was visualized with Alexa Fluor 594-conjugated phalloidin, and nuclei were stained with DAPI. Coverslips were mounted with Mounting Medium for Fluorescence (Vectashield; Vector Laboratories). Fluorescence microscopy images were obtained with a microscope (Axioplan2; Carl Zeiss, Inc.) equipped with a charge-coupled device camera (Axiocam HRm; Carl Zeiss, Inc.) using Axiovision software (Carl Zeiss, Inc.) at room temperature. All images of primary cells were taken with a 40× NA 0.75 objective. The A7r5 cells were imaged with a 63× NA 1.40 oil immersion objective. Confocal images were obtained with a microscope (Radiance 2100 MP; Bio-Rad Laboratories) using Laser Sharp 2000 software (Bio-Rad Laboratories) at room temperature (60× NA 1.4, zoom 7, Pix0.027 oil immersion objective). Postacquisition analyses were performed using Volocity software (PerkinElmer).
Podosome function and migration assays
Functional assays were performed essentially as described previously (Berdeaux et al., 2004) . Quantification of podosomes was performed on merged phalloidin-cortactin-stained samples on at least 50 randomly chosen fields representing 100 total cells per experimental point. Primary WT and KO cells containing at least one complete rosette of podosomes were scored as positive. A7r5 cells containing at least two punctate F-actin-rich podosomes were scored as positive. Total cell numbers were calculated by scoring the number of nuclei on the same field. Motility and invasion assays using Transwell chambers were conducted as described previously (Seals et al., 2005) , except that 10,000 cells were used in each assay and it was performed for 6 h. Adenovirus infection was performed 24 h before the assay, whereas PDBu was added directly to the culture medium during the seeding of the Boyden chamber (BD). PDGF was used as a chemoattractant.
Generation of adenoviral vectors harboring miRs
Adenovirus vectors were prepared as previously described (Carè et al., 2007; Elia et al., 2009a) . Cells were transduced at an MOI of 50 and checked for adequate transduction by quantitative RT-PCR (qRT-PCR). denaturation at 95°C (15 s) and annealing/extension at 60°C (60 s). This was preceded by reverse transcription at 42°C for 30 min and denaturation at 85°C for 5 min. Northern blotting was performed to confirm the expression levels of miR-143 and -145. Probes, antisense oligonucleotides against mature miR-143, -145, and -199, and U6 were LNA (locked nucleic acid) based (Exiqon).
Statistical analysis
Luciferase, RNA, protein, and migration values were compared using the two-tailed analysis of variance (ANOVA) test. A value of P < 0.05 or less was considered to be statistically significant.
Online supplemental material Fig. S1 shows clustering of KO SMC podosomes and inhibition by miR-143 and -145 expression. Fig. S2 shows the effect of miR-143 and -145 on podosome formation and the effect of doxorubicin on miR-143 and -145 levels. Fig. S3 shows the cellular localization and effect of knockdown of miR-143 and -145 targets in VSMCs. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200912096/DC1.
